A Pilot Study To Assess Feasbility Of Collection Of Prostate Cancer Cells In Peripheral Blood Using A Biotinylated Inhibitor (Biotin-Peg12-Ctt-54) Of The Enzyme-Biomarker PSMA And Culturing The Captured Prostate Cancer Cells In A Zebrafish Xenograft

Print this page

A Pilot Study To Assess Feasbility Of Collection Of Prostate Cancer Cells In Peripheral Blood Using A Biotinylated Inhibitor (Biotin-Peg12-Ctt-54) Of The Enzyme-Biomarker PSMA And Culturing The Captured Prostate Cancer Cells In A Zebrafish Xenograft

1. To determine the feasibility of capturing prostate cancer cells obtained from specimens of patient derived peripheral blood using a novel Biotin-PEG12-CTT-54 based capture technique

2. To determine the feasibility of culturing captured prostate cancer cells using the Biotin-PEG12-CTT-54 based capture in zebrafish.

3. To study the characteristics of captured stem cells including expression of the androgen receptor and other potential markers of sensitivity to prostate cancer therapeutics

4. To study the effects of therapeutics on prostate cancer in a zebrafish model.

Protocol Number081212
Principal InvestigatorMark Stein
PhasePilot
ScopeLocal
Applicable Disease SitesProstate
Participating InstitutionsRutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.